Chemours vs Ingevity: revenue, profit, margins and growth compared
Chemours brought in $5.8B of revenue in fiscal 2025, Ingevity $1.2B in fiscal 2025. Revenue changed by +0.4% at Chemours and -2.7% at Ingevity on the year before, so Chemours grew faster. Chemours kept -6.6% of its revenue as net profit, Ingevity -14.3%. Free cash flow was $51M at Chemours and $273.5M at Ingevity.
Fiscal years as each company reports them; the two may end in different months.
Questions about Chemours and Ingevity
Which is bigger by revenue, Chemours or Ingevity?
Chemours is bigger by revenue: $5.8B in fiscal 2025, against $1.2B for Ingevity in fiscal 2025.
Which keeps more of its revenue as profit, Chemours or Ingevity?
Chemours had a net margin of -6.6% in fiscal 2025; Ingevity had -14.3% in fiscal 2025.
Which grew revenue faster, Chemours or Ingevity?
In their latest fiscal years revenue changed by +0.4% at Chemours and -2.7% at Ingevity.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.